* NeuroSearch A/S, of Glostrup, Denmark, is offering 500,000 new shares on the Copenhagen Stock Exchange to raise DKra280 million. The proceeds will be used to advance lead compounds for the treatment of anxiety, dementia and depression, which are currently in Phase I studies, and compounds in preclinical studies, including treatments for epilepsy and cocaine addiction. The company's most advanced compound, brasofensine for the treatment of Parkinson's disease, is in Phase II trials.

No Comments